{"id":"https://openalex.org/W3032739665","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3053","title":"Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.","display_name":"Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3032739665","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3053","mag":"3032739665"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.3053","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3053","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.3053","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027645406","display_name":"Richard Lee O'Neal","orcid":"https://orcid.org/0000-0001-9081-1680","observed_orcids":["https://orcid.org/0000-0001-9081-1680"]},"institutions":[{"id":"https://openalex.org/I143302722","display_name":"University of Kentucky","ror":"https://ror.org/02k3smh20","country_code":"US","type":"education","lineage":["https://openalex.org/I143302722"]},{"id":"https://openalex.org/I2802239656","display_name":"Markey Cancer Center","ror":"https://ror.org/01dhvva97","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285210727","https://openalex.org/I143302722","https://openalex.org/I2802239656"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Lee O'Neal","raw_affiliation_strings":["University of Kentucky, Markey Cancer Center, Greenville, KY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Kentucky, Markey Cancer Center, Greenville, KY;","institution_ids":["https://openalex.org/I143302722","https://openalex.org/I2802239656"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042172036","display_name":"Kandice Roberts","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I143302722","display_name":"University of Kentucky","ror":"https://ror.org/02k3smh20","country_code":"US","type":"education","lineage":["https://openalex.org/I143302722"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kandice Roberts","raw_affiliation_strings":["University of Kentucky College of Medicine, Lexington, KY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Kentucky College of Medicine, Lexington, KY;","institution_ids":["https://openalex.org/I143302722"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071987481","display_name":"Zhonglin Hao","orcid":"https://orcid.org/0000-0003-4638-0814","observed_orcids":["https://orcid.org/0000-0003-4638-0814"]},"institutions":[{"id":"https://openalex.org/I143302722","display_name":"University of Kentucky","ror":"https://ror.org/02k3smh20","country_code":"US","type":"education","lineage":["https://openalex.org/I143302722"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhonglin Hao","raw_affiliation_strings":["University of Kentucky, Lexington, KY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Kentucky, Lexington, KY;","institution_ids":["https://openalex.org/I143302722"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030064179","display_name":"Susanne M. Arnold","orcid":"https://orcid.org/0000-0001-6542-9551","observed_orcids":["https://orcid.org/0000-0001-6542-9551"]},"institutions":[{"id":"https://openalex.org/I143302722","display_name":"University of Kentucky","ror":"https://ror.org/02k3smh20","country_code":"US","type":"education","lineage":["https://openalex.org/I143302722"]},{"id":"https://openalex.org/I2802239656","display_name":"Markey Cancer Center","ror":"https://ror.org/01dhvva97","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285210727","https://openalex.org/I143302722","https://openalex.org/I2802239656"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susanne M. Arnold","raw_affiliation_strings":["Markey Cancer Center, University of Kentucky, Lexington, KY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Markey Cancer Center, University of Kentucky, Lexington, KY;","institution_ids":["https://openalex.org/I143302722","https://openalex.org/I2802239656"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"3053","last_page":"3053"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8679999709129333},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9850000143051147},{"id":"https://openalex.org/keywords/rechallenge","display_name":"drug rechallenge","score":0.6869999766349792},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.7929999828338623},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.9300000071525574},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.9990000128746033},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6330000162124634},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.5410000085830688},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9710000157356262},{"id":"https://openalex.org/keywords/kidney-cancer","display_name":"kidney cancer","score":0.8289999961853027},{"id":"https://openalex.org/keywords/bladder-cancer","display_name":"bladder cancer","score":0.9490000009536743},{"id":"https://openalex.org/keywords/irae-management","display_name":"irAE management","score":0.4819999933242798},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.5849999785423279},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-related-pneumonitis","display_name":"immune-related pneumonitis","score":0.5879999995231628},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.828000009059906},{"id":"https://openalex.org/keywords/immune-related-dermatitis","display_name":"immune-related dermatitis","score":0.9340000152587891},{"id":"https://openalex.org/keywords/immune-related-hepatitis","display_name":"immune-related hepatitis","score":0.9860000014305115}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9318093061447144},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7196561694145203},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6471484303474426},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5603682398796082},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49831223487854004},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4940257668495178},{"id":"https://openalex.org/C2779524853","wikidata":"https://www.wikidata.org/wiki/Q1284347","display_name":"Pneumonitis","level":3,"score":0.4618052840232849},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4545038342475891},{"id":"https://openalex.org/C2777793932","wikidata":"https://www.wikidata.org/wiki/Q1116229","display_name":"Common Terminology Criteria for Adverse Events","level":3,"score":0.42904454469680786},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36183831095695496},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3502978980541229},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2714300751686096},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.17463409900665283}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.3053","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3053","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.3053","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4295836826","https://openalex.org/W4281643811","https://openalex.org/W3134535644","https://openalex.org/W4290614506","https://openalex.org/W7162489190","https://openalex.org/W4417302771","https://openalex.org/W3114253099","https://openalex.org/W7214202288","https://openalex.org/W2948397884","https://openalex.org/W3016806376"],"abstract_inverted_index":{"3053":[0],"Background:":[1],"Immune":[2],"checkpoint":[3],"inhibition":[4],"(ICI)":[5],"with":[6,25,189,314,346,380,394],"cytotoxic":[7],"T-lymphocyte":[8],"antigen":[9],"4":[10],"(CTLA-4),":[11],"programmed":[12,17],"death":[13,18],"1":[14],"(PD-1),":[15],"or":[16],"ligand-1":[19],"(PD-L1)":[20],"blockade":[21],"can":[22,37],"be":[23,38,397],"associated":[24,313,379],"the":[26,48,171,204,363],"development":[27],"of":[28,35,44,94,99,102,108,203,227,237,282,285,297,341,362,374],"immune":[29],"related":[30],"adverse":[31],"events":[32],"(irAE),":[33],"many":[34],"which":[36],"treatment-limiting.":[39],"Due":[40],"to":[41,53,76,91,117,224,295,335,354,370,384],"an":[42,303,407],"absence":[43],"randomized":[45],"controlled":[46],"trials,":[47],"current":[49],"approach":[50],"in":[51,83,245,258,317,399],"regards":[52],"ICI":[54,68,111,126,175,306,333,395],"discontinuation":[55],"versus":[56],"rechallenging":[57,393],"remains":[58],"controversial.":[59],"Methods:":[60],"We":[61],"assessed":[62],"all":[63],"patients":[64,124,172,247,286,349],"who":[65,80,173,216,248,260,287,299,331,386],"had":[66,81,155,174,193,200,223,288,337,369],"received":[67,125],"at":[69],"a":[70,156,201,211,228,232,250,289,308,315,356,360,375],"single":[71],"academic":[72],"institution":[73],"from":[74,147,280],"5/2015":[75,148],"1/2019,":[77],"identifying":[78],"those":[79,215,246,259,298,385],"delays":[82],"their":[84],"treatment.":[85,347],"Retrospective":[86],"chart":[87],"review":[88],"was":[89,112,242,255,311,378],"performed":[90],"determine":[92],"type":[93,96],"ICI,":[95,190,283],"and":[97,104,106,142,167,207,254,366],"grade":[98],"irAE,":[100,103,206,365],"treatment":[101,251],"recurrence":[105,202,361],"grades":[107],"irAE":[109,158,253,291,310,377],"if":[110],"resumed,":[113],"as":[114,116,352,359],"well":[115],"assess":[118],"overall":[119],"survival":[120],"(OS).":[121],"Results:":[122],"562":[123],"(lung":[127],"cancer":[128,135,139],"[232,":[129],"41%],":[130],"melanoma":[131],"[66,":[132],"12%],":[133],"kidney":[134],"[43,":[136],"8%],":[137],"bladder":[138],"[27,":[140],"5%],":[141],"other":[143],"cancers":[144],"[194,":[145],"34.5%])":[146],"\u2013":[149,272,324],"1/2019.":[150],"Of":[151,170,214],"these,":[152],"121":[153],"(22%)":[154],"treatment-limiting":[157,196,290,309,376],"(most":[159],"commonly":[160],"dermatitis":[161],"[24%],":[162],"colitis":[163],"[17%],":[164],"pneumonitis":[165],"[14%],":[166],"hepatitis":[168],"[12%]).":[169],"held,":[176],"80/121":[177],"(66%)":[178],"were":[179,217,292,350],"eventually":[180],"rechallenged,":[181,218],"while":[182],"41/121":[183],"(34%)":[184],"discontinued":[185,332],"permanently.":[186,372],"When":[187],"rechallenged":[188,345],"47/80":[191],"(59%)":[192],"no":[194],"further":[195],"irAEs,":[197],"16/80":[198],"(20%)":[199],"same":[205],"17/80":[208,220],"(21%)":[209,221],"developed":[210],"different":[212],"irAE.":[213,230],"only":[219],"ultimately":[222],"discontinue":[225,371],"because":[226],"second":[229],"At":[231,277],"median":[233,240],"follow":[234],"up":[235],"time":[236],"12.1":[238],"months,":[239],"OS":[241,318,382],"not":[243,262,301,312,405],"reached":[244],"experienced":[249],"limiting":[252],"8.1":[256],"months":[257,279],"did":[261,300,387,404],"(hazard":[263],"ratio":[264],"[HR]":[265],"for":[266],"death,":[267],"0.33;":[268],"95%":[269],"CI":[270,322],"0.23":[271],"0.48;":[273],"p":[274,326],"<":[275],"0.001).":[276],"12":[278],"initiation":[281],"77.0%":[284],"alive,":[293],"compared":[294,383],"39.6%":[296],"have":[302,406],"event.":[304],"Restarting":[305],"after":[307],"change":[316],"(HR":[319],"0.66":[320],"[95%":[321],"0.27":[323],"1.66],":[325],"=":[327],"0.38).":[328],"Conclusions:":[329],"Patients":[330],"secondary":[334],"irAEs":[336],"relatively":[338,367],"low":[339],"rates":[340],"recurrent":[342],"toxicity":[343,358],"when":[344],"These":[348],"just":[351],"likely":[353],"develop":[355],"new":[357],"original":[364],"few":[368],"Development":[373],"improved":[381],"not.":[388],"This":[389],"study":[390],"suggests":[391],"that":[392],"may":[396],"safe":[398],"selected":[400],"patients,":[401],"though":[402],"this":[403],"impact":[408],"on":[409],"OS.":[410]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2020-06-05T00:00:00"}